ABSTRACT: The purpose of this study was to examine whether the substitution of the Lys linker with the β-Ala could reduce the renal uptake of 99m Tc-labeled Arg-X-Asp-conjugated and X-Ala-Aspconjugated α-melanocyte stimulating hormone (α-MSH) peptides. RSD-β-Ala-(Arg 11 )CCMSH (1) {c[Arg-Ser-Asp-DTyr-Asp]-β-Ala-CysCys-Glu-His-DPhe-Arg-Trp-Cys-Arg-Pro-Val-NH 2 }, RTD-β-Ala-(Arg 11 )CCMSH (2), RVD-β-Ala-(Arg 11 )CCMSH (3), RAD-β-Ala-(Arg 11 )CCMSH (4), NAD-β-Ala-(Arg
■ INTRODUCTION
Melanocortin 1 (MC1) receptor is an attractive molecular target for melanoma imaging because of its overexpression on both murine and human melanoma cells. 1−16 Recently, we have identified a class of 99m Tc-labeled α-melanocyte stimulating hormone (α-MSH) peptides to target MC1 receptors for melanoma imaging. Specifically, the cyclic RXD motifs {Arg-XAsp-DTyr-Asp, X = Gly, Ala, Val, Thr, Ser, Nle, Phe, and DPhe} were attached to [Cys 3, 4, 10 ,D-Phe 7 ,Arg 11 ]α-MSH 3−13 via a lysine linker to yield RXD-Lys-(Arg 11 )CCMSH peptides. Interestingly, single amino acid at the X position yielded a profound impact on the melanoma targeting and clearance properties of 99m Tc-RXDLys-(Arg 11 )CCMSH peptides. For instance, the substitution of Gly in 99m Tc-RGD-Lys-(Arg 11 )CCMSH with Ala, Thr, Val, and Ser improved the MC1 receptor binding affinities and enhanced the melanoma uptake in B16/F1 melanoma-bearing C57 mice. 17−19 On the other hand, the substitution of Gly in TcRfD-Lys-(Arg 11 )CCMSH exhibited much higher liver uptake as compared to 99m Tc-RGD-Lys-(Arg 11 )CCMSH. 18 Despite the promising melanoma targeting results, extremely high renal uptake (67−135% ID/g at 2 h postinjection) is a common issue associated with 99m Tc-RXD-Lys-(Arg 11 )CCMSH peptides. 17−19 Thus, it is desirable to reduce the nonspecific renal uptake of 99m Tc-RXD-Lys-(Arg 11 )CCMSH peptides to facilitate their potential therapeutic applications. In our previous reports, L-lysine co-injection significantly reduced the renal uptake of 99m Tc-RXD-Lys-(Arg 11 )CCMSH peptides by 37%−51% at 2 h postinjection without affecting their tumor uptake. 17−19 L-Lysine is a positively charged amino acid. The effect of L-lysine coinjection in reducing the renal uptake indicated that the overall positive charges of 99m Tc-RXD-Lys-(Arg 11 )CCMSH peptides contributed to their nonspecific renal uptake. Obviously, the substitution of the positively charged Lys linker with a neutral amino acid can decrease the overall charges of 99m Tc-RXD-Lys-(Arg 11 )CCMSH peptides. According to the effect of L-lysine coinjection in decreasing the renal uptake, we hypothesized that the substitution of the Lys linker with a neutral β-Ala linker would decrease the renal uptake of 99m Tc-RXD-Lys-(Arg 11 )CCMSH peptides. To examine our hypothesis, we synthesized six peptides with β-Ala linkers, namely, peptides 1−6. The MC1 receptor binding affinities of these six peptides were examined in B16/F1 melanoma cells. The peptides were readily radiolabeled with 99m Tc using SnCl 2 as a reducing agent. We further determined the biodistribution properties in B16/F1 melanoma-bearing C57 mice for these six 99m Tc-peptides. Thereafter, we determined the imaging property of 99m Tc-4 in B16/F1 melanoma-bearing C57 mice.
■ RESULTS
The schematic structures of six new peptides are presented in Figure 1 . The peptides were synthesized and purified by reverse phase-high performance liquid chromatography (RP-HPLC) according to our previously published procedures. 17, 18 The overall synthetic yields were 25−30% for all six peptides. The chemical purities of the peptides were greater than 95% after the HPLC purification ( Table 1 ). The peptide identities were confirmed by electrospray mass spectrometry. The measured molecular weight was 2123 Da for peptide 1, 2137 Da for peptide 2, 2135 Da for peptide 3, 2107 Da for peptide 4, 2064 Da for peptide 5, and 2080 Da for peptide 6 ( Table 1 ). The competitive binding curves of the peptides are shown in Figure 2 . The IC 50 value was 2.76 ± 0.51 nM for peptide 1, 1.56 ± 0.63 nM for peptide 2, 1.99 ± 0.16 nM for peptide 3, 0.35 ± 0.01 nM for peptide 4, 3.34 ± 0.28 nM for peptide 5, and 3.84 ± 0.71 nM for peptide 6 in B16/F1 melanoma cells, respectively.
All six peptides were readily radiolabeled with co-injection on the renal uptake of 99m Tc-4 at 2 h postinjection is presented in Figure 4 . Co-injection of 15 mg of L-lysine significantly (p < 0.05) reduced the renal uptake of 99m Tc-4 from 20.18 ± 3.86% ID/g to 13.06 ± 3.62% ID/g without significantly affecting the tumor uptake at 2 h postinjection.
Because 99m Tc-4 showed the highest tumor uptake and the lowest renal uptake than the other five 99m Tc-peptides at 2 h postinjection, we further determined the tumor imaging property, specificity of tumor uptake, and urinary metabolites of 99m Tc-4 in B16/F1 melanoma-bearing C57 mice. Whole-body SPECT/CT image at 2 h postinjection is presented in Figure 5 . Flank B16/F1 melanoma lesions were clearly visualized by SPECT using 99m Tc-4 as an imaging probe. The SPECT image of tumor accurately matched its anatomical location obtained in the CT image. The SPECT image showed high contrast of tumor to normal organ except for kidneys, which was consistent with the biodistribution results. As shown in Figure 5 , the tumor uptake was blocked by unlabeled NDP-MSH, demonstrating that the tumor uptake was receptor-mediated. The urinary metabolites of 99m Tc-4 at 2 h postinjection are shown in Figure 6 .
99m Tc-4 remained intact in the urine at 2 h postinjection.
■ DISCUSSION
In our previous reports, 17−19 we have found the importance of single amino acid at the X position in the tumor targeting properties of peptides were approximately 2-fold weaker than RXD-Lys-(Arg 11 )CCMSH peptides, respectively. Despite the fact that the -His-DPhe-Arg-Trp-motif is the binding moiety for the MC1 receptor, the decrease in receptor binding affinity with the β-Ala linker substitution indicated that the linker might somehow interact with the receptor binding moiety. Such interaction might be related to the side chain of the Lys linker. The decrease in receptor binding affinities of RXD-β-Ala-(Arg 11 )CCMSH peptides also resulted in the reduction in tumor uptake of 99m Tc-RXD-β-Ala-(Arg 11 )CCMSH peptides by 21−45% in a The data are presented as percent injected dose/gram or as percent injected dose (mean ± SD, n = 4). b ( * ) p < 0.05 for determining the significance of differences in tumor and kidney uptake between a The data are presented as percent injected dose/gram or as percent injected dose (mean ± SD, n = 4). b ( * ) p < 0.05 for determining the significance of differences in tumor and kidney uptake between Tc-RAD-Lys-(Arg 11 )CCMSH at 2 h postinjection. 19 It is worthwhile to note that there is a positively charged Arg residue in the RAD moiety of 99m Tc-4. Thus, we a The data are presented as percent injected dose/gram or as percent injected dose (mean ± SD, n = 4). b ( * ) p < 0.05 for determining the significance of differences in tumor and kidney uptake between a The data are presented as percent injected dose/gram or as percent injected dose (mean ± SD, n = 4). b ( * ) p < 0.05 for determining the significance of differences in tumor and kidney uptake between Tc-peptides investigated in this study. Thus, we further examined its melanoma imaging property and urinary metabolites. The B16/F1 melanoma lesions could be clearly visualized by SPECT/CT using 99m Tc-4 as an imaging probe. a The data are presented as percent injected dose/gram or as percent injected dose (mean ± SD, n = 4). b ( * ) p < 0.05 for determining the significance of differences in tumor and kidney uptake between a The data are presented as percent injected dose/gram or as percent injected dose (mean ± SD, n = 4). b ( * ) p < 0.05 for determining the significance of differences in tumor and kidney uptake between 99m Tc-6 with or without NDP-MSH peptide blockade at 2 h postinjection. Tc(EDDA)-HYNIC-GGNle-CycMSH hex (7.52 ± 0.96% ID/g). The difference in renal uptake was likely due to the structural differences among these 99m Tc-peptides. Interestingly, we found that L-lysine co-injection significantly reduced the renal uptake of 99m Tc-4 by 35% at 2 h postinjection without affecting its tumor uptake significantly (Figure 4) . Therefore, L-lysine co-injection could be utilized to further decrease the renal uptake of 188 Re-RAD-Lys-(Arg 11 )CCMSH to facilitate its potential therapeutic application.
Journal of Medicinal Chemistry

■ CONCLUSIONS
The substitution of the Lys linker with the β-Ala linker dramatically decreased the renal uptake of characterization by MS, each protected peptide was dissolved in H 2 O/CH 3 CN (50:50) and lyophilized to remove the reagents such as TFA and triisopropylsilane. Each protected peptide was further cyclized by coupling the carboxylic group from the Asp with the α amino group from the Arg, Nle, or Glu at the N-terminus. The cyclization reaction was achieved by overnight reaction in dimethylformamide (DMF) using benzotriazole-1-yl-oxy-tris-pyrrolidinophosphonium hexafluorophosphate (PyBOP) as a coupling agent in the presence of N,N-diisopropylethylamine (DIPEA). The protecting groups were totally removed by treating with a mixture of TFA, thioanisole, phenol, water, ethanedithiol, and triisopropylsilane (87.5:2.5:2.5:2.5:2.5:2.5) for 2 h at room temperature (25°C). Each peptide was precipitated and washed with ice-cold ether four times, purified by RP-HPLC, and characterized by liquid chromatography−mass spectrometry (LC− MS). The chemical purity of each peptide was determined by Waters RP-HPLC instrument (Milford, MA) on a Grace Vydac C-18 reverse phase analytic column (Deerfield, IL) using a 20 min gradient of 18−28% acetonitrile in 20 mM HCl aqueous solution at a flow rate of 1 mL/min. The purities of all six peptides were greater than 95%.
The IC 50 values of the peptides for the MC1 receptor were determined in B16/F1 melanoma cells. The competitive receptor binding assay was replicated in triplicate for each peptide. The B16/F1 cells were seeded into a 24-well cell culture plate at a density of 2. Tc-6 were determined by incubation in mouse serum at 37°C for 24 h and monitored for degradation by RP-HPLC. Briefly, 100 μL of each HPLCpurified peptide solution (∼7.4 MBq) was added into 100 μL of mouse serum (Sigma-Aldrich Corp, St. Louis, MO) and incubated at 37°C for 24 h. After the incubation, 200 μL of a mixture of ethanol and acetonitrile (v:v = 1:1) was added to precipitate the serum proteins. The resulting mixture was centrifuged at 16000g for 5 min to collect the supernatant. The supernatant was purged with N 2 gas for 30 min to remove the ethanol and acetonitrile. The resulting sample was mixed with 500 μL of water and injected into RP-HPLC for analysis using the gradient described above.
Biodistribution Studies. All the animal studies were conducted in compliance with Institutional Animal Care and Use Committee approval (12- Tc-peptide via the tail vein. Groups of four mice were sacrificed at 0.5, 2, 4, and 24 h postinjection, and tumors and organs of interest were harvested, weighed, and counted. Blood values were taken as 6.5% of the body weight. The specificity of tumor uptake was determined by co-injecting each 99m Tc-peptide with 10 μg (6.1 nmol) of unlabeled NDP-MSH at 2 h postinjection.
The effect of L-lysine co-injection on the renal uptake of 99m Tc-4 was examined in B16/F1 melanoma-bearing C57. A group of four mice were injected with an aqueous mixture of 0.037 MBq of 99m Tc-4 and 15 mg of L-lysine. The mice were sacrificed at 2 h postinjection, and tumor and kidneys were harvested, weighed, and counted.
Melanoma Imaging with 99m Tc-4. Tc-4 was the lead peptide because of its highest tumor uptake and the lowest renal uptake. Thus, we further determined the melanoma imaging property of 99m Tc-4 and the specificity of melanoma uptake. Approximately 3.7−4.1 MBq of 99m Tc-4 with or without 10 μg (6.1 nmol) of unlabeled NDP-MSH was injected into B16/F1 melanoma-bearing C57 mice via the tail vein, respectively. The mice were euthanized for small animal SPECT/CT (Nano-SPECT/CT, Bioscan, Washington, DC) imaging 2 h postinjection. The 9 min CT imaging was immediately followed by the SPECT imaging of whole body. The SPECT scans of 24 projections were acquired. Reconstructed data from SPECT and CT were visualized and co-registered using InVivoScope (Bioscan, Washington, DC).
Urinary Metabolites of 99m Tc-4. We also examined the urinary metabolites of 99m Tc-4. Approximately 3.7 MBq of 99m Tc-4 was injected into a B16/F1 melanoma-bearing C57 mouse via the tail vein to determine the urinary metabolites. The mouse was euthanized to collect urine at 2 h postinjection. The collected urine sample was centrifuged at 16000g for 5 min before the HPLC analysis. Thereafter, an aliquot of the urine was injected into the HPLC. A 20 min gradient of 16−26% acetonitrile/20 mM HCl with a flow rate of 1 mL/min was used for urine analysis.
Statistical Analysis. Statistical analysis was performed using the Student's t test for unpaired data to determine the significance of differences in tumor and kidney uptake with/without peptide blockade in biodistribution studies described above. Differences at the 95% confidence level (p < 0.05) were considered significant.
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